促红细胞生成素对慢性充血性心力衰竭患者心肌细胞凋亡的影响——附31例检测分析  

Effects of erythropoietin on the cardiac function and myocardial apoptosis in patients with chronic heart failure

作　　者：程颖[1] 解强[1] 冯燕玲[1] 吴钰燕[1] 李劲草[1] 卓裕丰[1] 张鹏[1] 林桂雄[1] 黄冰生[1] 

机构地区：[1]南方医科大学附属何贤纪念医院心内科,511400

出　　处：《新医学》2012年第5期300-303,共4页Journal of New Medicine

基　　金：广州市番禺区科技局科技计划项目(2011-Z-03-39)

摘　　要：目的:探讨促红细胞生成素(EPO)对慢性充血性心力衰竭(CHF)患者心功能及心肌细胞凋亡的影响。方法:选择CHF患者62例,随机分为EPO治疗组与对照组各31例,两组患者均接受规范的CHF药物治疗,EPO治疗组在此基础上再接受每周2次重组人EPO 2 000 U皮下注射,疗程3个月。比较研究初始及结束时两组患者的血常规、脑钠肽、可溶性凋亡相关因子(sFas)、可溶性凋亡相关因子配体(sFasL)及心脏彩声多普勒超声结果;观察两组患者心血管事件发生率。结果:研究结束时,EPO治疗组患者血浆脑钠肽、sFas、sFasL水平及因心力衰竭再次住院率均明显低于对照组(P均﹤0.05);对照组患者血红蛋白水平较EPO治疗组略有降低,但两组比较差异无统计学意义;两组间LVEF比较差异无统计学意义(P>0.05)。两组治疗过程中均无出现明显不良反应。结论:在规范的CHF治疗基础上,对CHF患者加用小剂量EPO,可减少患者的贫血及心肌细胞凋亡发生率,改善心功能,并可减少再次因心力衰竭住院率,安全性高。Objective： To investigate the effects of erythropoietin （EPO） on the cardiac function and myocar- dial apoptosis in patients with chronic heart failure （CHF）. Methods： Sixty-two patients with CHF were recruited to this study and randomly divided into two groups ： control group （ n = 31 ） and EPO treatment group （ n = 31 ）. The patients in EPO treatment group were given with routine treatment for CHF and EPO （2000 U, hypodermic injection, twice every week, for 3 months）. All subjects were followed up for 3 months. The levels of hemoglobin, serum sFas, sFasL, BNP and LVEF were assessed at beginning and the end of study. The cardiovascular events were recorded. Results： Significant reduction of sFas, sFasL, BNP and heart failure rehospitalization were revealed in EPO treatment group （P 〈 0. 05）. Although lower hemoglobin was reported in control group, there was no significant difference. No adverse event was reported. Conclusion： On the basis of standard therapy＇ extra EPO treatment alleviates anemia, improves cardiac function, and inhibits myocardial apoptosis, thus reduces rehospitalization of heart failure.

关 键 词：心力衰竭 促红细胞生成素 心功能 凋亡 

分 类 号：R541.6[医药卫生—心血管疾病]